Abstract. Melioidosis caused by Burkholderia pseudomallei is endemic in southeast Asia. The clinical manifestations range from wound infections to acute septicemia. In some cases, recurrence can also occur following complete recovery. Case fatality rates are high and a major factor is the delay in the culture and identification of the bacterium. An immunofluorescent assay (IFAT) using whole-cell antigen for the detection of total antibodies to B. pseudomallei was tested with 650 sera. Using a cut-off value of 1:80, 66 sera from culture-confirmed cases were positive with titers Ն320. In another 523 sera from patients in which no other etiology could be found, 149 (23.4%) were positive. To monitor disease activity, persistence of antibody levels was investigated on 61 serial sera samples collected from 14 other confirmed cases on follow-up visits while on oral maintenance therapy. The IFAT demonstrated a reduction in titers in cases of localized infections, suggesting that either the infection was being resolved or arrested while septicemic patients maintained high IFAT titers on follow-up, suggesting the possibility of continuous sequestration of antigen from an intracellular source.
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Melioidosis, an infectious disease of humans and animals caused by Burkholderia pseudomallei, a soil saprophyte, and endemic in southeast Asia and northern Australia, is becoming a serious public health problem. The clinical manifestations are protean in nature, ranging from wound infections to acute septicemia. In some cases, relapse and recurrence can occur after several weeks, months, or even years following complete clinical recovery. Mortality is high among patients with underlying risk factors such as uncontrolled diabetes or immunosuppression. Due to these reasons, a purely clinical diagnosis is not possible.
The current gold standard for a definitive diagnosis of melioidosis is the isolation and identification of the causative agent (B. pseudomallei) from various clinical specimens, which may take 3-7 days. 1 However, in many peripheral laboratories in endemic areas, there is a lack of awareness as well as facilities for the accurate identification of this organism. Therefore, the unavailability of an alternative rapid test with a high level of sensitivity and specificity for melioidosis hampers treatment with appropriate antimicrobials, thus leading to septicemia, septic shock, acute respiratory failure, and eventually death.
To date, a variety of immunologic tests have been developed for the diagnosis of melioidosis. These include an indirect hemagglutination assay (IHAT), 2 an immunofluorescent assay (IFAT), 3 and an enzyme immunosorbent assay (EIA), 4 but none of them have been used extensively in clinical practice to diagnose or monitor patients with melioidosis. The major problem with these assays has been the low specificity of the antigenic sequences, leading to cross-reactions with infections caused by other Burkholderia and Pseudomonas species, as well as with Legionella species. 4 A previous study on the seroepidemiology of melioidosis with 378 sera demonstrated that an IgM-capture ELISA and the IFAT both using whole cell antigens had a sensitivity and specificity of 100% when compared with culture. 5 However, the IFAT also showed positive results in 8% of patients with fever, diabetes mellitus, pregnant women, and healthy outdoor workers, suggesting true infections or cross-reactions. 4 Based on this study, we evaluated the usefulness of the IFAT in the serodiagnosis of melioidosis and in monitoring disease activity in patients on long-term oral maintenance therapy.
MATERIALS AND METHODS
Bacterial identification. Burkholderia pseudomallei was isolated from pus, wound swabs, or blood and confirmed using standard biochemical tests and the API 20NE System (Bio-Merieux, Marcy l'Etoile, France). The cultures were further confirmed by slide agglutination using B. pseudomallei polyvalent sera raised to whole cell antigen in rabbits.
Sera. A total of 650 sera samples obtained from the Medical and Surgical Units of University Hospital (Universiti Malaya), and from various government and private hospitals in East and West Malaysia were used in this study. Of these, 127 were from culture-confirmed cases and included 66 single samples from individual patients and an additional 61 samples collected serially from 14 other patients who complied with follow-up visits and maintenance therapy. The remaining 523 sera were tested with the melioidosis-IFAT only when laboratory test results for other known infections in endemic areas such as tuberculosis, typhoid fever, leptospirosis, rickettsial fevers, and typhus were negative. Additionally, another important criterion was the presentation of clinical features suggestive of melioidosis such as prolonged fever, non-healing wounds, and ulcers in diabetics, community-acquired pneumonia, abscesses, cellulitis, empyema, pleural effusions, unresolved cough, and non-healing wounds following trauma in young patients and children with cervical lymphadenopathy in whom tuberculosis had been excluded.
The IFAT for detection of total antibodies to melioidosis. The assay was performed as described by Ashdown 3 with modifications. Briefly, the antigen was coated, air-dried, and heat-fixed onto the wells of teflon-coated slides. 5 Each serum sample was prepared in doubling dilutions from 1:80 to 1:320 and allowed to incubate at 37ЊC for 30 min, after which the slide was washed 3 times in phosphate-buffered saline (PBS) (pH 7.4) prior to the addition of fluoresceinlabeled anti-human IgM/IgG antibodies (Jackson Laboratories, West Grove, PA). Following incubation for an additional 30 min, the slide was washed 3 times in PBS (pH 7.4), air-dried, mounted with buffered glycerol, and viewed under an ultraviolet microscope. Results were scored as 3ϩ, 2ϩ, 1ϩ, or negative compared with positive and negative control sera. The lower limit for a positive cut-off value was a score of 1ϩ at a dilution of 1:80. Sera samples demonstrating a fluorescence intensity of 3ϩ or 2ϩ at a dilution of 320 were considered to have a titer Ն320. For follow-up cases, each serum sample was tested at dilutions of 1:20-1:320. A negative score up to a dilution of 1:40 was considered a negative result. Positive sera included those from B. pseudomallei culture-positive patients and negative controls were sera collected for other tests from newborns.
RESULTS
Screening of culture-confirmed cases by the IFAT. Single sera samples from 66 culture-confirmed cases were positive in the IFAT with titers Ն320. The sera from newborn infants were negative.
Detection of total antibodies to melioidosis by the IFAT. Among the 523 sera tested that were negative for other infections, 149 (23.4%) were positive by the IFAT, as determined by a cut-off value of 1:80. The titers of these samples were Ն160, with the majority (Ͼ90%) having a titer Ն320. The remaining 374 samples were negative, i.e., titers Ͻ80. Analysis of the sera based on geographic distribution demonstrated that in the metropolitan area of Kuala Lumpur, 18.8-20% of sera were IFAT-positive among those suspected of having melioidosis. However, a higher rate of 38.4% was obtained for samples from Sibu/Kapit Hospitals in East Malaysia. The number of sera from the other centers was too small to be analyzed separately.
Persistence of antibody after clinical recovery. Disease activity was monitored by the IFAT on 61 serial samples from 14 patients. Except for 1 serum sample, the initial serum taken prior to administration of melioidosis-specific treatment for all of these patients was positive with a titer Ն320 (Tables 1 and 2 ). Of the 6 adult cases, 3 were septicemic, 1 had septic arthritis of the hip and knee, and 2 had localized superficial infections. The IFAT tested on sera taken at follow-up showed a reduction in the titers of cases with localized infections over a period of 20-28 months, indicating successful treatment and possible eradication of the organism from the host (Table 1 ; patients B and C). However, in the 3 patients (D, E, and F) who had septicemia and in the 1 patient (A) with septic arthritis, the titers never decreased below 320 over a period of 1-3 years.
Similar sequential serologic procedures were carried out on 8 patients who were initially diagnosed as having acute melioidosis based on the clinical features, high IFAT titers, and non-response to antimicrobials that were not specific for melioidosis. All of these patients were children 2-11 years of age and 5 (62.5%) of 8 had cervical lymphadenopathy and/or abscesses in the liver and spleen (Table 2) . Three patients (A, B, and G) showed a reduction in titers over a period of 9-10 months, but they required further monitoring of disease activity. Of the 5 other children, 3 (E, F, and H) showed a reduction in titers over a period of 4-18 months, 1 (D) showed no change, and the other (C) demonstrated an increase of 1 log titer when tested between 3 and 6 months.
DISCUSSION
Immunologic assays for the diagnosis of infectious diseases have always been received and interpreted with caution because of the variability and specificity of antigens available. As a result, culturing of the etiologic agent has always been considered the gold standard. Nevertheless, there are many situations when patients are critically ill with fulminating sepsis or when infections are deep seated and no specimens are available, where serology may be sufficiently rapid to facilitate aggressive and appropriate treatment and management of patients.
The clinical manifestations of melioidosis being protean in nature has often led to the non-diagnosis of this disease resulting in unnecessary morbidity and mortality. Many patients with longstanding localized infections may go to a hospital only when secondary septicemia results with complications and rapid deterioration. It has been emphasized that the rapidity of a definitive diagnosis of melioidosis is crucial to the reduction of the associated high mortality. 6 The problems due to the prolonged and unknown incubation period as well as partially treated cases augment the difficulty of a correct diagnosis. Another important consideration is that the organism can remain dormant or latent despite appropriate and aggressive antibiotic therapy during the acute phase, resulting in relapse and recrudescence at various times. [7] [8] [9] Thus, maintenance therapy with appropriate antibiotics is necessary.
There are no well-established guidelines for the duration of maintenance antibiotic therapy, although 3-6 months have been mentioned in many reports. 10 In our experience, relapse or recurrence of signs and symptoms have occurred while patients were on maintenance therapy and also after completion of 6 months of antibiotics, with the signs and symptoms appearing between 2 and 6 years later. During this time, the antibody levels measured at intervals of 1-2 months remained high (Vadivelu J, Puthucheary SD, unpublished data). These were adult patients with diabetes and other underlying immunocompromised states.
In children with melioidosis, from a different geographical area and possibly a hot spot for B. pseudomallei, the initial high antibody levels were found to taper down during maintenance therapy and therapy was stopped when the titer decreased below diagnostic levels. The children were followed-up for an average of two years and remained symptom free. Thus, we believe that serological follow-up may be useful as a guideline to the duration of oral maintenance therapy.
The absence of a well-established universally acceptable antigen has made the serologic diagnosis of melioidosis very difficult and controversial. Antigens such as culture filtrates, 11 purified exotoxin, 12 as well as a 19.5-kD polypeptide purified from a bacterial cell extract, 13 have been tested with less than satisfactory results. However, none of these tests have been used extensively in clinical practice and their diagnostic usefulness or value is not known. We have been using the IFAT at the University Hospital over the last five years and in the present study describe the use of this assay in the diagnosis and management of patients with melioidosis. An important criterion is that very often the stage of the disease activity is not known; therefore, the estimation of total antibodies is necessary as opposed to estimating only IgM or IgG. In addition, a more conservative cut-off value of 1:80 was used as opposed to 1:40 to differentiate true infections from increased background titers due to basal antibody levels in endemic areas. 3, 5, 11, 14 In this study, 66 single sera from patients with cultureconfirmed melioidosis were positive in the IFAT with high titers Ն320 and negative control sera from newborns were negative. The IFAT results were also positive in 149 (23.4%) of 523 sera from cases in which no other cause was established. This figure is high, although some of these cases resulted in fatalities because the patients presented with septicemia and tests for melioidosis were requested only when all other causes were excluded. However, in the pediatric cases, the test proved to be helpful in successfully managing patients as rapid and aggressive treatment with antimicrobials specific for melioidosis were initiated. In this study, the high proportion of cases from the Sibu/Kapit Hospitals in East Malaysia may be due to changes in the environment because these hospitals serve a catchment area that was undergoing a huge deforestation program for the construction of a dam, thus reemphasizing the habitat of the organism. Many of the patients from these hospitals were either inhabitants of the area or construction workers of this particular project and all of the pediatric cases were from this area.
The IFAT was useful in monitoring the progression of the disease during maintenance therapy. Sixty-one sera obtained serially from 14 patients with localized non-septicemic infections and on maintenance therapy demonstrated reduction in titers (Tables 1 and 2 ). This decrease in titer on followup suggests that the infection was either being resolved or arrested. In contrast, among patients who had developed septicemia, the titer remained at a high level (Ͼ320), suggesting the continuous sequestration of antigen or organism from an intracellular or cryptic site in the host. This further emphasizes the notion that the organism does remain latent in the host following clinical recovery since some of these patients were clinically well on follow-up visits. Among the pediatric cases, there was a decrease in titers (Table 2) indicating that in a healthy, immunocompetent, young individual given appropriate therapy at an early stage, it may be possible to overcome the long-term survival of the bacterium in vivo. In addition, these findings also demonstrate the need to follow-up patients with melioidosis, even though they are clinically asymptotic, until there is serologic evidence that the infection has resolved.
In conclusion, this study found serology to be useful and rapid (3 hr) in the diagnosis of melioidosis. The findings also demonstrated the need to include melioidosis as one of the differential diagnosis in patients with fevers in endemic areas and in travelers since there have been reports of people contracting melioidosis following travel to these areas. To date, there are no studies that offer guidelines on monitoring the disease activity in patients with melioidosis or in defining a time frame for maintenance antibiotic therapy. The present study provides evidence that monitoring does help assess disease activity as demonstrated by levels of antibodies and that maintenance therapy should also continue at least until the titers begin to decrease.
